Frequent reduction or loss of DCC gene expression in human osteosarcoma.

Standard

Frequent reduction or loss of DCC gene expression in human osteosarcoma. / Horstmann, Martin; Pösl, M; Scholz, R B; Anderegg, B; Simon, P; Baumgaertl, K; Delling, G; Kabisch, H.

In: BRIT J CANCER, Vol. 75, No. 9, 9, 1997, p. 1309-1317.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Horstmann, M, Pösl, M, Scholz, RB, Anderegg, B, Simon, P, Baumgaertl, K, Delling, G & Kabisch, H 1997, 'Frequent reduction or loss of DCC gene expression in human osteosarcoma.', BRIT J CANCER, vol. 75, no. 9, 9, pp. 1309-1317. <http://www.ncbi.nlm.nih.gov/pubmed/9155051?dopt=Citation>

APA

Horstmann, M., Pösl, M., Scholz, R. B., Anderegg, B., Simon, P., Baumgaertl, K., Delling, G., & Kabisch, H. (1997). Frequent reduction or loss of DCC gene expression in human osteosarcoma. BRIT J CANCER, 75(9), 1309-1317. [9]. http://www.ncbi.nlm.nih.gov/pubmed/9155051?dopt=Citation

Vancouver

Horstmann M, Pösl M, Scholz RB, Anderegg B, Simon P, Baumgaertl K et al. Frequent reduction or loss of DCC gene expression in human osteosarcoma. BRIT J CANCER. 1997;75(9):1309-1317. 9.

Bibtex

@article{b9c255991e454e0b8e1a3b36657767ff,
title = "Frequent reduction or loss of DCC gene expression in human osteosarcoma.",
abstract = "The 'deleted in colon carcinoma' (DCC) gene has been considered a candidate tumour-suppressor gene that encodes for a transmembrane protein with strong structural similarity to members of the superfamily of neural cell adhesion molecules. It has been mapped to the chromosomal region 18q21.1 and it is implicated in cellular differentiation and developmental processes. In human osteosarcoma allelic loss frequently occurs on the long arm of chromosome 18, suggesting a possible involvement of the DCC gene in the pathogenesis of this tumour entity. In the present study the mRNA and protein expression and rearrangements at the DNA level of the DCC gene were addressed in 25 osteosarcomas and several tumour cell lines, including osteosarcoma- and colon carcinoma-derived cell lines. Using an reverse transcriptase polymerase chain reach in (RT-PCR)-based approach DCC expression was found to be lost or substantially reduced in 14 of 19 high-grade osteosarcomas, in three of six lower grade osteosarcomas and most of the tumour cell lines, in contrast to normally differentiated osteoblasts. Immunohistochemical studies on DCC protein expression of 14 selected tumours correlated well with the RT-PCR-based results. In view of the putative tumour-suppressor characteristics of the DCC gene its loss or reduction of expression could be a specific event in the development or progression of many high-grade osteosarcomas.",
author = "Martin Horstmann and M P{\"o}sl and Scholz, {R B} and B Anderegg and P Simon and K Baumgaertl and G Delling and H Kabisch",
year = "1997",
language = "Deutsch",
volume = "75",
pages = "1309--1317",
journal = "BRIT J CANCER",
issn = "0007-0920",
publisher = "NATURE PUBLISHING GROUP",
number = "9",

}

RIS

TY - JOUR

T1 - Frequent reduction or loss of DCC gene expression in human osteosarcoma.

AU - Horstmann, Martin

AU - Pösl, M

AU - Scholz, R B

AU - Anderegg, B

AU - Simon, P

AU - Baumgaertl, K

AU - Delling, G

AU - Kabisch, H

PY - 1997

Y1 - 1997

N2 - The 'deleted in colon carcinoma' (DCC) gene has been considered a candidate tumour-suppressor gene that encodes for a transmembrane protein with strong structural similarity to members of the superfamily of neural cell adhesion molecules. It has been mapped to the chromosomal region 18q21.1 and it is implicated in cellular differentiation and developmental processes. In human osteosarcoma allelic loss frequently occurs on the long arm of chromosome 18, suggesting a possible involvement of the DCC gene in the pathogenesis of this tumour entity. In the present study the mRNA and protein expression and rearrangements at the DNA level of the DCC gene were addressed in 25 osteosarcomas and several tumour cell lines, including osteosarcoma- and colon carcinoma-derived cell lines. Using an reverse transcriptase polymerase chain reach in (RT-PCR)-based approach DCC expression was found to be lost or substantially reduced in 14 of 19 high-grade osteosarcomas, in three of six lower grade osteosarcomas and most of the tumour cell lines, in contrast to normally differentiated osteoblasts. Immunohistochemical studies on DCC protein expression of 14 selected tumours correlated well with the RT-PCR-based results. In view of the putative tumour-suppressor characteristics of the DCC gene its loss or reduction of expression could be a specific event in the development or progression of many high-grade osteosarcomas.

AB - The 'deleted in colon carcinoma' (DCC) gene has been considered a candidate tumour-suppressor gene that encodes for a transmembrane protein with strong structural similarity to members of the superfamily of neural cell adhesion molecules. It has been mapped to the chromosomal region 18q21.1 and it is implicated in cellular differentiation and developmental processes. In human osteosarcoma allelic loss frequently occurs on the long arm of chromosome 18, suggesting a possible involvement of the DCC gene in the pathogenesis of this tumour entity. In the present study the mRNA and protein expression and rearrangements at the DNA level of the DCC gene were addressed in 25 osteosarcomas and several tumour cell lines, including osteosarcoma- and colon carcinoma-derived cell lines. Using an reverse transcriptase polymerase chain reach in (RT-PCR)-based approach DCC expression was found to be lost or substantially reduced in 14 of 19 high-grade osteosarcomas, in three of six lower grade osteosarcomas and most of the tumour cell lines, in contrast to normally differentiated osteoblasts. Immunohistochemical studies on DCC protein expression of 14 selected tumours correlated well with the RT-PCR-based results. In view of the putative tumour-suppressor characteristics of the DCC gene its loss or reduction of expression could be a specific event in the development or progression of many high-grade osteosarcomas.

M3 - SCORING: Zeitschriftenaufsatz

VL - 75

SP - 1309

EP - 1317

JO - BRIT J CANCER

JF - BRIT J CANCER

SN - 0007-0920

IS - 9

M1 - 9

ER -